Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma
Leo Meriranta, Amjad Alkodsi, Annika Pasanen, Maija Lepistö, Parisa Mapar, Yngvild Nuvin Blaker, Judit Jørgensen, Marja‐Liisa Karjalainen‐Lindsberg, Idun Fiskvik, Lars Tore Gyland Mikalsen, Matias Autio, Magnus Björkholm, Mats Jerkeman, Øystein Fluge, Peter de Nully Brown, Sirkku Jyrkkiö, Harald Holte, Esa Pitkänen, Pekka Ellonen, Sirpa Leppä
Abstract
Inadequate molecular and clinical stratification of the patients with high-risk diffuse large B-cell lymphoma (DLBCL) is a clinical challenge hampering the establishment of personalized therapeutic options. We studied the translational significance of liquid biopsy in a uniformly treated trial cohort. Pretreatment circulating tumor DNA (ctDNA) revealed hidden clinical and biological heterogeneity, and high ctDNA burden determined increased risk of relapse and death independently of conventional risk factors. Genomic dissection of pretreatment ctDNA revealed translationally relevant phenotypic, molecular, and prognostic information that extended beyond diagnostic tissue biopsies. During therapy, chemorefractory lymphomas exhibited diverging ctDNA kinetics, whereas end-of-therapy negativity for minimal residual disease (MRD) characterized cured patients and resolved clinical enigmas, including false residual PET positivity. Furthermore, we discovered fragmentation disparities in the cell-free DNA that characterize lymphoma-derived ctDNA and, as a proof-of-concept for their clinical application, used machine learning to show that end-of-therapy fragmentation patterns predict outcome. Altogether, we have discovered novel molecular determinants in the liquid biopsy that can noninvasively guide treatment decisions.